Patient Guide to Support Services

Takeda Oncology

1Point
844-817-6468
Velcade Reimbursement Assistance Program
866-835-2233

Takeda Oncology 1Point program offers comprehensive services that can assist patients with coverage support, financial assistance, and other day-to-day needs associated with Alunbrig (brigatinib), Ninlaro (ixazomib), or Iclusig (ponatinib) treatment. Takeda Oncology 1Point program may be able to provide assistance for eligible patients with all insurance types through the Co‑Pay Assistance Program, the RapidStart Program, and the Patient Assistance Program.

The list of Takeda Oncology medications, their indications, and programs is provided in the Table.

Takeda Oncology also offers a suite of services and resources to practices and eligible patients seeking access to Velcade (bortezomib) through the Velcade Reimbursement Assistance Program (VRAP).

Takeda Oncology 1Point Patient Services

  • Assisting eligible patients with out-of-pocket costs
  • Helping patients understand their insurance coverage for Ninlaro, Alunbrig, or Iclusig
  • Providing information about specialty pharmacies that can help patients get Ninlaro, Alunbrig, or Iclusig
  • Helping eligible patients start therapy as quickly as possible, as directed by their physician
  • Connecting patients to additional resources, such as legal services, counseling and support programs, emotional support, and transportation assistance.

VRAP Patient Services

  • Financial assistance
  • Navigation through reimbursement processes and concerns
  • Support and resources for the insured, uninsured, and underinsured.

Eligibility

Co-Pay Assistance Program

Patients with private insurance who may have difficulties paying for Alunbrig, Iclusig, or Ninlaro may be eligible for the Co-Pay Assistance Program. For patients prescribed Alunbrig, Iclusig, or Ninlaro, this copay program covers out-of-pocket expenses of >$10 for a monthly prescription, with a maximum benefit of $25,000 annually. The copay card can be renewed every 12 months.

Patients are not eligible to participate if their prescription is covered by any federal or state healthcare program, including Medicare, Medicaid, TRICARE, or Medicare Part D; or insurance that is paying the entire cost of the prescription.

RapidStart Program

Patients prescribed Alunbrig, Iclusig, or Ninlaro may be eligible to receive a free 1-cycle (28-day) supply if they are experiencing a delay in insurance coverage of ≥5 business days. Other eligibility criteria include:

  • Having an appropriate diagnosis for Alunbrig, Inclusig, or Ninlaro for an FDA-approved indication
  • Receiving a new prescription for Alunbrig, Iclusig, or Ninlaro
  • Having insurance coverage.

Takeda Oncology Patient Assistance Program

The Patient Assistance Program offers free monthly supplies of Ninlaro, Alunbrig, or Iclusig to patients who have no insurance or are underinsured. Eligibility depends on the number of members in the household and the annual gross household income. Patients must have a valid prescription for Ninlaro, Alunbrig, or Iclusig and must provide household income verification.

Velcade Reimbursement Assistance Program

VRAP is available to all patients receiving Velcade, regardless of their financial and insurance situations. Enrollment in VRAP provides access to a case manager to share support options and resources to facilitate therapy. For more information visit Velcade.com/paying-for-treatment.

Velcade Patient Assistance Program

Patients residing in the United States who have no insurance coverage for Velcade may be eligible to participate in the Patient Assistance Program. Eligibility is based on the treatment setting, household income, US residency, and a prescription for the FDA-approved use of Velcade.

Application & Enrollment

Takeda Oncology 1Point

Enrollment in the Takeda Oncology 1Point program for patients using Alunbrig, Iclusig, or Ninlaro requires that the physician and the patient complete the enrollment form, and fax it to 844-269-3038.

Patient health insurance information and verification of income may be required based on the applicant’s request for services. Takeda Oncology 1Point will contact the physician’s office once the benefit verification is complete and will provide patients with a summary of benefits within 2 business days of the receipt of all required information.

Enrollment in the Takeda Oncology 1Point Co-Pay Assistance Program is also medication-specific. Patients can enroll in the Co-Pay Assistance Program for Alunbrig, Iclusig, or Ninlaro at TakedaOncology1Point.com or by calling 844-817-6468.

After patients have enrolled, they will receive a letter in the mail from Takeda Oncology 1Point containing their copay card.

Patients interested in participating in the RapidStart Program should notify their physicians so that they can complete the RapidStart Request form located under the Access Support section at TakedaOncology1Point.com.

Patients interested in participating in the Patient Assistance Program should complete the Patient Assistance Program application with their physician.

The application for Alunbrig, Iclusig, and Ninlaro is available online.

If the patient is approved for this program, the patient and his or her physician will be notified and a 1-month supply of the medication will be mailed to the patient.

Each month, the physician’s office must confirm that the patient is still being treated with Ninlaro, Alunbrig, or Iclusig and requires another month’s supply of the drug. Eligible patients can be enrolled for up to 1 year.

VRAP

Enrollment in VRAP requires the completion of the enrollment form, and faxing it to 800-891-9843.

Patients need to coordinate with their healthcare provider to complete this form to include the diagnosis (including the diagnosis code), route of administration, the patient’s previous therapies, and the clinical service setting. The patient’s health insurance information and verification of income are also required.

Patients are eligible to participate in VRAP for 1 year, as long as they continue to meet the program’s qualifications. They can re-enroll after 12 months if they continue to use Velcade.

Table Takeda Oncology Drugs

Drugs
Indications
Patient support programs

Drug
Alunbrig (brigatinib) tablets
Indication
Metastatic non–small-cell lung cancer with ALK mutation in patients whose disease progressed during, or who are intolerant of, crizotinib theorapy

Drug
Iclusig (ponatinib) tablets
Indication
Chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia; chronic myeloid leukemia with T315I mutation; Ph+ acute lymphoblastic leukemia with T315I mutation

Drug
Ninlaro (ixazomib)
Indication
Multiple myeloma, in combination with lenalidomide and dexamethasone

Drug
Velcade (bortezomib)
Indication
Multiple myeloma; mantle-cell lymphoma

Ph+ indicates Philadelphia chromosome–positive.

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: